Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?

4 days ago 6

Jonathan Ponciano, The Motley Fool

Wed, March 18, 2026 astatine 10:49 AM CDT 3 min read

Superstring Capital Management initiated a caller presumption successful Sionna Therapeutics (NASDAQ:SION), acquiring 180,593 shares successful the 4th quarter.

According to a February 17, 2026, SEC filing, Superstring Capital Management reported a caller involvement successful Sionna Therapeutics totaling 180,593 shares. The quarter-end worth of the presumption stood astatine $7.43 million.

This caller presumption represents 3.98% of Superstring’s 13F reportable AUM arsenic of December 31, 2025.
Top holdings aft the filing:
- NASDAQ:CDTX: $18.80 cardinal (10.1% of AUM)
- NASDAQ:TERN: $17.93 cardinal (9.6% of AUM)
- NASDAQ:URGN: $16.82 cardinal (9.0% of AUM)
- NASDAQ:COGT: $13.01 cardinal (7.0% of AUM)
- NASDAQ:DVAX: $8.08 cardinal (4.3% of AUM)
As of February 13, 2026, Sionna Therapeutics shares were priced astatine $34.99, up astir 144% implicit the past twelvemonth and acold surpassing the S&P 500’s astir 19% summation successful the aforesaid period.

Metric

Value

Price (as of Wednesday)	$34.99
Market capitalization	$1.6 billion
Net income (TTM)	($75.3 million)

Sionna Therapeutics develops biopharmaceutical therapies targeting cystic fibrosis, with a absorption connected medicines that reconstruct cystic fibrosis transmembrane conductance regulator (CFTR) function.
Headquartered successful Waltham, Massachusetts, the steadfast develops medicines for cystic fibrosis patients by normalizing the relation of the cystic fibrosis transmembrane conductance regulator.

Sionna Therapeutics, Inc. is simply a clinical-stage biotechnology institution specializing successful innovative therapies for cystic fibrosis. The company's strategy centers connected advancing a pipeline of CFTR modulators designed to code the underlying origin of the disease. With a focused attack to uncommon illness cause development, Sionna leverages technological expertise to prosecute differentiated treatments successful a competitory biopharmaceutical landscape.

As you mightiness expect from a biotech up arsenic overmuch arsenic Sionna this past year, the institution is heading into a agelong wherever aggregate objective updates could reshape its valuation, with Phase 1 and Phase 2 information expected successful the mediate of this year. That benignant of timeline creates a model wherever expectations tin displacement quickly, particularly successful a abstraction wherever differentiated mechanisms, similar targeting CFTR relation much directly, tin bid important capitalist attention.

Sionna’s had a blockbuster twelvemonth since its nationalist marketplace debut past February, arsenic evidenced by its staggering banal surge and affirmative Phase 1 trials, and financially, the institution is successful a comparatively beardown presumption for its stage. It ended the twelvemonth with astir $310 cardinal successful cash, providing runway into 2028 adjacent arsenic improvement spending continues to climb. That gives absorption flexibility to propulsion guardant without contiguous dilution pressure, which is not ever the lawsuit successful biotech.

Read Entire Article